Sulfonylated aminothiazoles as new small molecule inhibitors of protein phosphatases
摘要:
Based on a previously identified lead structure, SC-alpha alpha delta9, we have developed a versatile new chemical scaffold that can be readily modified to generate libraries of both Tyr and dual specificity phosphatase inhibitors with reduced molecular weight and lipophilicity. The most potent analogue identified to dare, aminothiazole 8z, inhibits the dual specificity phosphatase Cdc25B with a K-i of 4.6 +/- 0.4 muM and a Hill coefficient of 2. (C) 2001 Elsevier Science Ltd. Ail rights reserved.
Styrylamidines are prepared by treating styrylsulfonylamidines with base. The styrylamidines are effective in the prevention of aggregation of blood platelets and as analgesics. Compounds of the invention are also useful as anticonvulsants, diuretics and antihypertensive agents. The styrylsulfonylamidines of the invention which serve as precursors to the styrylamidines also have analgesic properties. Illustrative of the styrylamidines of the present invention are 4-amino-N-(4-aminostyryl)benzamidine and N-(3,4-dichlorostyryl)acetamidine. An example of a styrylsulfonylamidine is N-(styrylsulfonyl)acetamidine.
The invention provides compounds of formula (I)
wherein R
1
, R
3
, L
1
, L
2
, G
1
, G
2
, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.
Antioxidant, Anti-inflammatory, and Neuroprotective Effects of Novel Vinyl Sulfonate Compounds as Nrf2 Activator
作者:Ji Won Choi、Su Jeong Shin、Hyeon Ji Kim、Jong-Hyun Park、Hyeon Jeong Kim、Elijah Hwejin Lee、Ae Nim Pae、Yong Sun Bahn、Ki Duk Park
DOI:10.1021/acsmedchemlett.9b00163
日期:2019.7.11
and reported a novel vinyl sulfone (1) as an Nrf2 activator with therapeutic potential for Parkinson’s disease (PD). In this study, we changed the vinyl sulfone to vinyl sulfonamide or vinyl sulfonate to improve Nrf2 activating efficacy. We observed that the introduction of vinyl sulfonamide led to a reduction of the effects on Nrf2 activation, whereas vinyl sulfonate compounds exhibited superior activity
Bis-(Sulfonylamino) derivatives for use in therapy
申请人:Bylund Johan
公开号:US20100331321A1
公开(公告)日:2010-12-30
The invention provides compounds of formula (I) wherein R
1
,R
3
,L
1
,L
2
,G
1
,G
2
, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.